Under the assumptions of this analysis, the provision of SGLT2 inhibition as a prophylactic population-wide intervention dominates the “do nothing” status quo for men at risk of prostate cancer in the sense that it lowers health care costs and increases QALYs, but only if offered at zero cost (see Supplementary Table S6). The gene discussed is SLC5A2; the disease is prostate carcinoma.